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Abstract
Twenty Nocardia spp. isolated from ocular infections were iden-
tiﬁed by 16S rRNA gene sequencing and susceptibility was deter-
mined using the E-test (AB Biodisk, Sweden). Species
distribution among the 20 isolates was as follows: Nocardia levis
(n = 7), Nocardia farcinica (n = 3), Nocardia abscessus (n = 2),
Nocardia brasiliensis (n = 2), Nocardia amamiensis (n = 2), Nocardia
puris (n = 1), Nocardia beijingensis (n = 1), Nocardia otitidiscaviarum
(n = 1) and Nocardia thailandica (n = 1). All isolates were sensi-
tive to amikacin. Eighteen (90%) isolates were sensitive to tobra-
mycin, 11 (55%) to ciproﬂoxacin and gatiﬂoxacin, and seven
(35%) to azithromycin and clarithromycin. Molecular methods
are useful for the identiﬁcation and for the detection of Nocardia
species that have not so far been reported in human infections.
Keywords: N. amamiensis, N. thailandica, N. levis, N. puris, ocular
infections
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Nocardia cause a variety of human infections including cuta-
neous, pulmonary and systemic nocardiosis. The ocular
pathology of nocardiosis includes uveitis, exudative choroid-
itis, retinal abscess, retinal detachment, keratitis, scleritis
and iritis [1,2]. Molecular methods, especially advances in
DNA sequencing, and the increasing number of sequences
available in databases have contributed greatly to classifying
the genus Nocardia into several species [3,4]. Accurate iden-
tiﬁcation of Nocardia to the species level has become
increasingly important because differences among species
have emerged in terms of epidemiology, virulence, and anti-
biotic susceptibility [3]. The present study aimed to identify
the Nocardia spp. isolated from ocular infections and to
compare the susceptibility of different Nocardia species to
various antibiotics. This information can aid the manage-
ment of ocular infections.
Twenty Nocardia spp. isolated from ocular infections
between April 2006 and October 2008 were included in the
present study. Nineteen of the 20 were isolated from cor-
neal scrapings in patients with keratitis and one from a
scleral scraping in a patient with scleritis. All the organisms
were identiﬁed to species level by 16SrRNA gene sequenc-
ing. DNA was extracted from 72-h cultures of Nocardia using
the QIaAMP DNA mini kit (Qiagen GmbH, Hilden, Ger-
many). A 606-bp fragment of the 16S rRNA gene of Nocardia
was ampliﬁed as described by Rodriguez-Nava et al. [5].
Sequencing was performed with ﬂuorescence-labelled
dideoxynucleotide terminators using an ABI 3130 Xl auto-
mated sequencer in accordance with the manufacturer’s
instructions (PE Applied Biosystems, Foster City, CA, USA).
The sequences were analysed and identiﬁed using the MEGA-
BLAST search program of the GenBank databases and BIBI soft-
ware [6]. An isolate was assigned to a particular species if
the 16S rRNA sequence of the isolate was >99% similar to
the type strain of the most closely-related species as indi-
cated by both the NCBI BLAST and BIBI database programs
[5,6]. For further conﬁrmation of the species, a Neighbour-
joining tree based on the observed divergence was con-
structed using the PHYLO WIN software [5].
Antibiotic susceptibility of Nocardia to amikacin, azithro-
mycin, clarithromycin, ciproﬂoxacin, gatiﬂoxacin, and tobra-
mycin was tested by the E-test (AB Biodisk, Sweden). The
turbidity of the ﬁnal Nocardia inoculum was adjusted to the
McFarland 1.0 standard. The inoculum was swabbed onto
the Mueller–Hinton blood agar plate and four E-test strips
were applied to each plate. The plates were incubated at
37C for 48–72 h and the results were interpreted according
to CLSI guidelines [7].
All 20 Nocardia isolates from ocular infections showed a
very high similarity (99% to 100%) compared with the
deposit species sequences in the GenBank database. Species
distribution among the 20 isolates was: Nocardia levis (n = 7),
Nocardia farcinica (n = 3), Nocardia abscessus (n = 2), Nocardia
brasiliensis (n = 2), Nocardia amamiensis (n = 2), Nocardia puris
(n = 1), Nocardia beijingensis (n = 1), Nocardia otitidiscaviarum
(n = 1) and Nocardia thailandica (n = 1). A phylogenetic tree
based on 16SrRNA gene sequencing of our isolates and
other species of Nocardia isolated from ocular infections
deposited in GenBank is shown in Fig. 1. All 20 (100%)
isolates were sensitive to amikacin and 18 (90%) were sensi-
tive to tobramycin. Eleven (55%) isolates were sensitive to
ciproﬂoxacin and gatiﬂoxacin and seven (35%) to azithromy-
cin and clarithromycin. The MIC values for amikacin were
0.25–0.75 lg/ml, azithromycin 2–64 lg/ml, clarithromycin
2–64 lg/ml, ciproﬂoxacin 0.25–32 lg/ml, gatiﬂoxacin 0.25–
16 lg/ml and tobramycin 0.25–2 lg/ml. The MIC90 for ami-
kacin was 0.75 lg/ml, azithromycin 32 lg/ml, clarithromycin
32 lg/ml, ciproﬂoxacin 8 lg/ml, gatiﬂoxacin 8 lg/ml and for
tobramycin it was 1 lg/ml. The susceptibility of different
Nocardia species (with GenBank accession numbers) to dif-
ferent antibiotics is shown in Table 1.
The species associated with ocular infections include
Nocardia asteroides, N. brasiliensis, N. farcinica, Nocardia cyriaci-
georgica and N. otitidiscaviarum, Nocardia pseudobrasiliensis,
Nocardia asiatica, Nocardia neocaledoniensis, and Nocardia
arthritidis [1,8,9]. In the present study, N. levis isolates
accounted for 35% of the total isolates studied. Leger et al.
[10] reported infection with N. levis in a marine mammal.
Yassin and Hupfer (unpublished data) from Germany depos-
ited the sequence of N. levis isolated from sputum of a
patient with pneumonia in GenBank (Genbank accession
number AM746989). There have been two reports of N. pu-
ris isolated from human infections: one from a patient with
an abscess and the other from a patient with choroiditis
[11,12]. N. thailandica was ﬁrst identiﬁed and isolated from
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pus [13]. N. amamiensis was ﬁrst isolated from soil in a sug-
arcane ﬁeld in Japan [14]. In the present study, we identiﬁed
these rare species of Nocardia using 16S rRNA gene
sequencing; these have so far not been reported in ocular
infections. The ﬁndings obtained in the present study suggest
that molecular methods are useful for identiﬁcation and
detection of new or unusual species of Nocardia.
In 1988, Wallace et al. [3] reported six drug pattern types
among N. asteroides based on antimicrobial susceptibility.
Antimicrobial susceptibility testing of all isolates of Nocardia
is warranted until susceptibility data for large numbers of iso-
lates within the species become available. Published reports
on antibiotic susceptibility of Nocardia suggest that all species
of Nocardia are sensitive to amikacin [8,15]. The present
TABLE 1. Susceptibility of different Nocardia spp. to different antibiotics
Study isolate (GenBank
accession number)
Species Reference sequencea
accession number
% Similarity AK AZ CM CP GF TB
ASH1 (GQ340674) Nocardia levis AM746988 99.7 S S S S S S
ASH3 (GQ340675) Nocardia levis AM746988 99.9 S R R S S S
(GQ340676) Nocardia levis AM746988 99.9 S S S S S S
ASH5 (GQ340677) Nocardia levis AM746988 99.7 S S S R R S
ASH10 (GQ340678) Nocardia levis AM746988 99.7 S R R S S S
ASH14 (GQ340679) Nocardia levis AM746988 99.7 S R R R R S
ASH22 (GQ340680) Nocardia levis AM746988 100 S R R S S S
ASH 2 (GQ340673) Nocardia puris AY903618 100 S S R R R S
ASH7 (GQ340681) Nocardia brasiliensis AF430038 100 S R R S S S
ASH20 (GQ340682) Nocardia brasiliensis AF430038 100 S S S R R S
ASH9 (GQ340683) Nocardia abscessus AY544980 100 S S S S S S
ASH18 (GQ340684) Nocardia abscessus AY544980 100 S R R R R S
ASH13 (GQ340685) Nocardia farcinica AY756551 100 S S S S S S
ASH15 (GQ340686) Nocardia farcinica AY756551 100 S R R S S R
ASH19 (GQ340687) Nocardia farcinica AY756551 100 S R R R R R
ASH8 (GQ340688) Nocardia beijingensis AB094650 100 S R R S S S
ASH12 (GQ340689) Nocardia otitidiscaviarum AB201303 100 S R S R R S
ASH16 (GQ340690) Nocardia amamiensis AB275164 99.9 S R R S S S
ASH17 (GQ340691) Nocardia amamiensis AB275164 99.7 S R R R R S
ASH21 (GQ340672) Nocardia thailandica AB126874 100 S R R R R S
AK, Amikacin; AZ, Azithromycin; CM, Clarithromycin; CP, Ciproﬂoxacin; GF, Gatiﬂoxacin; TB, Tobramycin; S, sensitive; R, Resistant.
aGenabank Sequence to which similarity was observed.
Neighbor joining method
Observed divergence
1000 bootstrap replicates
0.008
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FIG. 1. Phylogenetic tree based on 16S rRNA gene sequencing constructed by the Neighbour-joining method.
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study conﬁrms the excellent in vitro activity of amikacin
against all Nocardia species, including N. amamiensis, N. thai-
landica, N. levis, and N. puris.
Antimicrobial susceptibility of Nocardia to ciproﬂoxacin
and clarithromycin also varies across species. Gulpczynski
et al. [15] from Brazil reported that several Nocardia species
including Nocardia nova, N. cyriacigeorgica, N. abscessus and
N. brasiliensis showed resistance to ciproﬂoxacin. Similarly,
they observed resistance to clarithromycin in all isolates of
N. cyriacigeorgica, N. brasiliensis and N. farcinica. In the present
study, we observed that only 55% of the isolates were sensi-
tive to ciproﬂoxacin and gatiﬂoxacin and only 35% were sen-
sitive to clarithromycin and azithromycin. Gatiﬂoxacin,
though a fourth-generation ﬂuoroquinolone, showed a sus-
ceptibility pattern similar to ciproﬂoxacin. Azithromycin is
available as a topical ophthalmic solution 1% (AzaSite; Inspire
Pharmaceuticals, Durham, NC, USA) and has been used in
the treatment of blepharitis and bacterial conjunctivitis
[16,17]. In the present study, we have tested the susceptibil-
ity of all the Nocardia isolates to azithromycin and found that
only 35% are sensitive to this drug. The in vitro susceptibility
results suggest that azithromycin is not a drug of choice for
nocardial ocular infections.
In conclusion, molecular methods are useful for the identi-
ﬁcation and detection of unusual species of Nocardia isolated
from clinical specimens. The present study conﬁrms the
excellent in vitro activity of amikacin against all Nocardia spp.,
including N. amamiensis, N. thailandica, N. levis and N. puris.
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